Scrambled, poached, or in a veggie omelet your GLP-1 levels won't know the difference, but your hunger hormones will

Choose GHRP-2 if: You want GH stimulation without intense hunger GHRP-2's milder appetite effect makes it more practical for those who don't want to deal with powerful hunger surges You're combining with a GHRH analog Both peptides synergize equally well with CJC-1295 or Sermorelin, but GHRP-2's lower appetite impact makes the combination more comfortable You're lean and trying to stay lean Intense hunger can sabotage body composition goals You want the most studied diagnostic variant GHRP-2 has more clinical validation as a pituitary function test Choose GHRP-6 if: Appetite stimulation is a feature, not a bug Recovery from illness, post-surgery, cachexia, or deliberate caloric surplus goals benefit from GHRP-6's orexigenic effect You're interested in cytoprotective applications GHRP-6 has a more extensive literature on cardioprotection, neuroprotection, and tissue protection (GHRP-6 cardioprotection, 2024) You're underweight or struggling to eat enough The appetite boost can be therapeutic You want the historical "first" GHRP GHRP-6 has the longest research track record in the family Choose Neither (Consider Alternatives) if: You want minimal side effects Ipamorelin (most selective GHSR-1a agonist) You want maximum GH potency Hexarelin (strongest GHRP, but highest cortisol/prolactin)

Endurance was evaluated by measuring the running time in seconds on the treadmill after 30 and after 60 days
The main draw of this supplement on top of its solid L-Carnitine content is the inclusion of creatine
Dermatologists can provide accurate, evidence-based information, guide patients towards using approved products, and encourage treatments performed by professionals holding a letter of credentialling and privileging, which is a certification that allows medical doctors to practise aesthetic medicine. She added that collaboration with the Health Ministry to enforce regulations and stop illegal medical practices is also critical
While likely safer than long-acting systemic analogs, IGF-1 DES is not without risks